Testimonials

Just wanted to let you know [Advisor] has been a great resource for [Client] in working up the multi-site trial. Her deep knowledge and professional attitude have been instrumental in our efforts to open this trial. We look forward to continuing work with Pearl.

 

Research Business Manager, Community-based health system

January, 2018

Thank you for the Site Activation Notification. I appreciate your diligent efforts and collaborative spirit in the process of getting the approvals.

Associate Dean for Research, U.S. health sciences university

October, 2017

Thank you for being so responsive to our urgent need for regulatory CMC input on the necessity of stability for over encapsulation of a comparator drug.

VP, Regulatory Affairs, Midsize clinical stage pharma company

June 2017

We wouldn’t be where we are today without Pearl Pathways. Their advisors’ expertise and flexibility helps keep us on track to overcome obstacles and meet deadlines. They have been there with us through the various ups and downs of our pharma startup.

CEO and Founder, Startup biopharma company

March 2017

We certainly look forward to working with you in the future as our plans for additional clinical research projects take shape.

In Vitro Diagnostics Manager, CLIA and CAP certified mycology reference laboratory

October, 2017

“Thank you so much for the speedy turnaround time [regarding the protocol review and research determination]. You and your team moved mountains!”

CRA, Multinational biopharma and medical device company

June 2017

I had a wonderful experience working with Pearl Pathways. They are a great group. Thereafter our initial engagement, I continue to try to give them more clients and business.

Director, Business Development, Biopharma development company

June 2017

Thank you, Pearl Pathways, for the thought you put into our study and the potential challenges you are helping us avert…thank you so much for bringing these issues to our attention and providing thoughtful solutions.

Chief Scientific Officer, Midsize biotech company

May 2017